CT Attenuation of Unilocular Pancreatic Cystic Lesions to Differentiate Pseudocysts from Mucin-Containing Cysts

Hamid Chalian, Hüseyin Gürkan Töre, Frank H Miller, Vahid Yaghmai

Department of Radiology, Northwestern Memorial Hospital, Northwestern University-Feinberg School of Medicine. Chicago, IL, USA

ABSTRACT

Context There is extensive overlap among the imaging characteristics of pseudocyst, mucinous cystic neoplasm (MCN) and side branch intraductal papillary mucinous neoplasm (IPMN) on CT images. Objective The purpose of this study was to evaluate the usefulness of attenuation measurement in differentiating pseudocysts from MCN and IPMN of pancreas on CT images. Patients Seventy-five pathologically proven unilocular pancreatic cysts including 31 pseudocysts, 29 MCN and 15 IPMN imaged with multidetector computed tomography (MDCT) before resection were evaluated. Main outcome measures Attenuation values were measured by conventional region of interest (ROI) method. Design Attenuation values (in Hounsfield unit, HU) were compared between the cyst pathologies. Receiver operating characteristic (ROC) curve analysis was performed to obtain the best attenuation threshold between mucin-containing cysts and pseudocysts. Correlation between attenuation values and cyst size was assessed. Results Maximum transaxial diameters of pseudocysts (4.5 cm), MCNs (3.7 cm) and IPMNs (4.0 cm) were comparable (P=0.919). Mean attenuation was 18.9 HU, 13.0 HU and 11.4 HU for pseudocyst, MCNs and IPMNs, respectively. Attenuations were significantly higher in pseudocysts versus mucin-containing (MCN+IPMN) cysts (P=0.001) and comparable between MCNs and IPMNs (P=0.390). ROC curve showed 14.5 HU the best cut-off (accuracy: 73.5%) for differentiating pseudocysts from mucin-containing cysts (P<0.001). Pancreatic cyst attenuation measurement did not significantly correlate with cyst size (r=-0.03, P=0.772). Conclusion Attenuation measurement may help in differentiating pseudocysts from unilocular mucin-containing simple cysts of the pancreas on CT images.

INTRODUCTION

Pancreatic cysts are being detected more frequently as an incidental finding at cross-sectional imaging [1, 2]. This is probably related to the recent improvements in high resolution imaging technologies such as multidetector computed tomography (MDCT). Incidental pancreatic cystic lesions have been reported to be detectable by 8.7% of MDCT images in the outpatient population imaged for diseases unrelated to the pancreas [2]. Inflammatory pseudocysts are common and complicate the course of chronic pancreatitis in up to 40% of patients [3]. However, pseudocysts may be detected incidentally in patients without known history of pancreatitis [4]. Serous cystadenomas, mucinous cystic neoplasms (MCN) and intraductal papillary mucinous neoplasms (IPMN) make up the majority of the non-inflammatory pancreatic cysts [5]. Clinical history of the patient, such as presence of previous pancreatitis, may be helpful in differentiating pancreatic cystic lesions. Imaging features help characterize different pancreatic cysts. In general, detecting a communication between a pancreatic cyst and main pancreatic duct favors the diagnosis of side branch IPMN [6]. Identification of microcystic morphology at imaging helps making a confident diagnosis of serous cystadenomas [7]. However, extensive overlap exists amongst the imaging characteristics of pseudocysts, MCNs and side branch IPMNs, when these cystic lesions are unilocular. Macari et al. found internal debris as a highly specific magnetic resonance (MR) finding for the differentiation of pseudocysts from non-inflammatory pancreatic cysts [8]. However, differentiation of pseudocysts from unilocular cystic neoplasms, especially MCNs and IPMNs is a major weakness of CT scanning [4, 9]. In this study we evaluated the role of cyst attenuation in differentiating unilocular...
pancreatic mucin-containing cystic neoplasms from pseudocysts at MDCT imaging.

METHODS AND MATERIALS

Study Sample

This is a retrospective Health Insurance Portability and Accountability Act (HIPAA) compliant study. Patient selection was performed in our institution’s surgical record database search engine using the following key words: “pancreatic cyst” and “MDCT”. Surgically proven MCN, IPMN and pseudocysts of pancreas during the period of January 2000 to June 2009 that had at least one MDCT before resection were included. Pancreatic cysts less than 1 centimeter were excluded to reduce the possibility of volume averaging error. Cysts with calcification, mural nodule or septa were excluded. Patients with stents within the pancreatic or common bile duct were also excluded. The study was designed to evaluate the ability of attenuation quantification at MDCT in differentiating unilocular pseudocysts from mucin-containing cysts of pancreas. One-hundred and twenty-nine pathologically proven pancreatic cysts were included. Eleven cysts were excluded due to maximum transaxial diameter less than 1 centimeter. Thirty-one cysts were excluded due to the presence of mural nodules, internal calcification or stent within the pancreatic or common bile duct. Twelve cysts were excluded for having visible septa inside them. Study population consisted of 75 unilocular pancreatic cysts including 31 pseudocysts, 29 MCNs and 15 IPMNs. Attenuation values were determined by conventional region of interest.

MDCT Imaging Protocol

All MDCT scans were obtained using Somatom Sensation 64 or 16-slice scanners (Siemens Medical Solutions, Erlangen, Germany) using 120 kVp, dose modulation with 270 reference mA with rotation speed of 0.5 s (Siemens Medical Solutions, Erlangen, Germany) or LightSpeed 4-slice scanner (GE Healthcare, Waukesha, WI, USA) using 120 kVp, 210 mA and rotation speed of 0.8 s. Image acquisition consisted of tri-phasic pancreatic protocol that included unenhanced images of the abdomen, followed by pancreatic parenchymal phase of the abdomen obtained at 40 seconds and portal venous phase of the abdomen and pelvis obtained at 70 seconds. Pancreatic parenchymal phase was obtained using a 0.6 mm or 0.75 mm MDCT scanners (Siemens Medical Solutions, Erlangen, Germany) or 1.25 mm collimation MDCT scanner (GE Healthcare, Waukesha, WI, USA) and 2 or 2.5 mm slice thickness during intravenous administration of 125 mL of iohexol-350 (GE Healthcare, Waukesha, WI, USA; total dose of iodine: 43.75 g) at the rate of 4 mL/s. Intravenous contrast was administered via an antecubital vein using an 18- or 20-gauge intravenous catheter and a mechanical injector (Stellant, Medrad, Indiana, PA, USA).

Image Analysis

Image analysis was performed on a picture archiving and communication system (PACS) workstation (Centricity RA1000, GE HealthCare, Barrington, IL, USA). For each cystic lesion, attenuation was measured by drawing a circular or elliptical region of interest (ROI) (range: ROI area: 0.23-11.2 cm², ROI pixels: 44-4,600) within the cyst’s greatest dimension in the transaxial plane. Care was taken not to include the normal pancreatic tissue during placement of the ROI (Figure 1). Mean attenuation value (in Hounsfield units, HU) which represents the mean attenuation of all pixels within the ROI and maximum transaxial diameter of the cyst were recorded.

Image analysis was performed by two readers in consensus (with six and two years of experience in CT interpretation, respectively) using the pancreatic parenchymal phase images. Readers were not involved in patient selection and were blind to the pathological diagnosis of the lesions. All studies that met the inclusion criteria were analyzed. Since pseudocysts change over time, we used the first available CT in our center for measurement of the attenuation and size.

ETHICS

This study was approved by our institutional review board. Patient informed consent was waived.

STATISTICS

Statistical analyses were performed using MedCalc for Windows, version 9.6.4.0 (MedCalc Software, Mariakerke, Belgium). Quantitative data were expressed as mean, 95% confidence interval (95% CI), and range. One-way analysis of variance (ANOVA) was performed to evaluate differences of maximum transaxial diameter and attenuation value over cyst pathologies. Tukey’s post hoc test was done to find significant pair-wise differences in case ANOVA
showed a statistically significant difference. Receiver operating characteristic (ROC) curve analysis was done to identify the cut-off in CT attenuation for differentiating pseudocysts from mucin-containing cysts of the pancreas. The best cut-off of the ROC curve was evaluated by means of a maximum likelihood method [10]. To evaluate the effect of cyst size on attenuation values, correlation of maximum transaxial diameter with attenuation values was assessed by Pearson correlation coefficient. The chi-squared test was used to evaluate whether different cyst types have been evenly distributed in the pancreas. The significance level was set at two-tailed P=0.05.

RESULTS

Demographics

Seventy-five patients with pathologically proven unilocular pancreatic cystic lesions (31 pseudocysts, 29 MCN and 15 IPMN) that underwent MDCT before resection were included. Different cyst types were not evenly distributed in the pancreas (P=0.002): 21 (28.0%) cysts were located in the head, 34 (45.3%) in the body and 20 (26.7%) in the tail of pancreas. Study population consisted of 30 males and 45 females, with a mean age of 56 years (95% CI: 52-61 years; range: 19-84 years). No significant difference was observed in the mean age between females (55 years; 95% CI: 49-61 years; range: 19-84 years) and males (57 years; 95% CI: 52-62 years; range: 31-77 years) (P=0.605).

Maximum Transaxial Diameter

Mean values for maximum transaxial diameter was 3.9 cm (95% CI: 3.2-4.5 cm; range: 1.1-16.4 cm) in the whole cohort, 4.5 cm (95% CI: 2.7-5.3 cm; range: 1.1-16.4 cm) in pseudocysts, 3.7 cm (95% CI: 2.8-4.6 cm; range: 1.2-10.4 cm) in MCN and 4.0 cm (95% CI: 3.1-4.7 cm; range: 2.1-7.4 cm) in IPMN (P=0.919).

Cyst Attenuation

Attenuation of pseudocysts (mean: 18.9 HU; 95% CI: 15-22.7 HU; range: 2.4-56.1 HU) was significantly higher than MCN (mean: 13 HU, 95% CI: 10.6-15.5 HU; range: 4.5-34.7 HU; P=0.014) and IPMN (mean: 11.4 HU; 95% CI: 8.8-14.1 HU; range: 5.9-23.3 HU; P=0.013). Attenuation of the MCN was comparable with attenuation of IPMN (P=0.390). Attenuation of the mucin-containing cysts (MCN+IPMN) (mean: 12.5 HU, 95% CI: 10.7-14.3 HU; range: 4.5-34.7 HU) was significantly lower than pseudocysts (P=0.001) (Figure 2). There were no outliers in the study population. ROC curve analysis (AUC=0.735; P<0.001 vs. the null hypothesis of AUC=0.5) showed an accuracy of 73.5% and 14.5 HU was identified as the best cut-off to differentiate pseudocysts from mucin-containing cysts of pancreas. Sensitivity (32/43, 74.4%) and specificity (23/32, 71.9%) of this cut-off were also measured (Figure 3).

Attenuation was not correlated with maximum transaxial diameter in the entire cohort (r: -0.03; P=0.772), pseudocysts (r: -0.08; P=0.665), MCN (r: 0.24, P=0.202) or IPMN (r: 0.29, P=0.290).

DISCUSSION

Advances in imaging technologies have resulted in more frequent detection of pancreatic cystic lesions [11, 12]. Most pancreatic cysts have an inflammatory origin. Serous cystadenomas, MCNs and IPMNs consist more than 90% of non-inflammatory pancreatic cysts [13]. Management of the inflammatory pancreatic cysts is quite different from non-inflammatory pancreatic cysts. Mucin-containing pancreatic cysts have malignant potential [14, 15] and may be resected, depending on the risk factors such as lesion size or age of the patient [13, 16]. Therefore, distinction of these cysts from pseudocysts of the pancreas is essential for their appropriate management [14].

History of pancreatitis for identification of pseudocysts, although useful, is not a consistent
clinical finding and can be seen in IPMNs and mucinous cystic neoplasms. A number of findings at imaging have been found to be useful for differentiating pseudocysts form pancreatic cystic lesions [7, 14, 17]. However, extensive overlap exists among the imaging characteristics of pseudocysts, MCNs and side branch IPMNs on CT images, making their differentiation difficult. Serous cystadenoma has a benign nature and has imaging characteristics that help distinguish it from other cystic lesions of pancreas [7, 17]. Identification of microcystic morphology at imaging helps making a confident imaging diagnosis of most serous cystadenomas which are microcystic [7]. Since most serous cystadenomas are identifiable based on their typical imaging features, we did not include serous cystadenomas in this study. When clinical and imaging evaluation does not help identify the nature of the pancreatic cysts, endoscopic ultrasonography with aspiration of the cyst fluid will help characterize the cyst type [18, 19].

Our results show that CT attenuation values may be helpful in distinguishing unilocular mucin-containing cystic lesions of the pancreas from pancreatic pseudocysts. Our results suggest CT attenuation of 14.5 HU a significant cut-off that is 74% accurate for differentiating pseudocysts form mucin-containing cysts of the pancreas. Procacci et al. have reported the accuracy of 60% for CT findings in diagnosing cystic pancreatic lesions [20]. The contribution of attenuation to the accuracy of diagnosis when accounting for all morphological features of these cystic lesions needs further evaluation. Significantly higher attenuation values were observed in pseudocysts compared with the mucin-containing cysts of pancreas. In a previous study, Macari et al. reported detectable internal debris on MR images of 13 out of 20 pseudocysts. They found that presence of internal dependent debris was a highly specific finding for the differentiation of pancreatic pseudocysts versus non-inflammatory cysts on MR images [8]. The debris inside the pseudocysts is due to the necrotic portions of pancreatic tissue remained within the cyst during the cyst formation. Unlike MR images on which debris is easily depicted [8, 21], internal debris is not well identifiable on CT images; however, presence of debris and hemorrhagic or proteinaceous material might explain the higher attenuation values of pseudocysts on CT images in our study. Mucinous cystic neoplasm and IPMN of pancreas had similar attenuation. However, IPMN may usually be distinguished from other cystic neoplasms of the pancreas by its connection to the pancreatic duct [6].

Our study had limitations. Apart from the intrinsic limits of any retrospective study, some other limitations should be mentioned. Region of interest measurement samples the largest portion of the cysts so it may be subject to sampling bias. This may be particularly true when there is a difference in attenuation in different parts of the cysts. We also did not evaluate the attenuation value of unilocular serous cystadenoma. Although there are specific imaging features that help differentiate macrocystic serous cystadenoma form MCN and pseudocysts [17], attenuation value might aid in this regard and requires further study. CT attenuation values may vary between different scanners [22]. We did not evaluate inter-scanner variability of CT attenuation in this study.

In conclusion, the results of our study suggest that unilocular pseudocysts tend to have higher attenuation value than unilocular mucin-containing cysts of the pancreas. We found CT attenuation of 14.5 HU a statistically significant cut-off for differentiating pseudocysts form mucin-containing cysts of the pancreas. Therefore, attenuation measurement may aid in differentiating these cystic lesions on CT images.

**Acknowledgment of grant** Dr. Hamid Chalian and Dr. Hüseyin Gürkan Töre were supported by educational grant from Siemens Healthcare, Erlangen, Germany

**Conflict of interest** The authors have no potential conflict of interest

**References**